Study M1011
Study name | Chi XS 2022 |
Title | Mechanism of lily bulb and Rehmannia decoction in the treatment of lipopolysaccharide-induced depression-like rats based on metabolomics study and network pharmacology |
Overall design | The aim of this study was to investigate the metabolic mechanism of lily bulb and Rehmannia decoction in treating depression in the lipopolysaccharide induced depression model. Sprague-Dawley rats were divided into the following 4 groups (n = 12 in each group): (1) control group, (2) lipopolysaccharide group, (3) lipopolysaccharide + lily bulb and Rehmannia decoction group (lipopolysaccharide injection with lily bulb and Rehmannia decoction treatment at the dose of 90.0 g/kg), and (4) lipopolysaccharide + fluoxetine group (lipopolysaccharide injection with fluoxetine treatment at the dose of 2 mg/kg). Lipopolysaccharide or saline were administered by intraperitoneal injection at a dose of 0.3 mg/kg to the rats for 14 days. After intervention with lipopolysaccharide for 3 days, drugs were then administered by gavage for 2 weeks. Prefrontal metabolites of rats were detected by using liquid chromatography-mass spectrometry metabolomics method (n = 6/group). |
Study Type | Type1; Type2; |
Data available | Unavailable |
Organism | Rat; Sprague-Dawley rat; |
Categories of depression | Animal model; Lipopolysaccharide induced depression model; Lipopolysaccharide induced depression model; |
Criteria for depression | Sucrose preference test, forced swimming test |
Sample size | 24 |
Tissue | Central; Brain; Medial prefrontal cortex; |
Platform | MS-based; LC-MS: ACQUITY UHPLC system (Waters Corporation, Milford, MA) with AB SCIEX Triple TOF 5600 System (AB SCIEX, Framingham, MA); |
PMID | |
DOI | |
Citation | Chi X, Xue X, Pan J, et al. Mechanism of lily bulb and Rehmannia decoction in the treatment of lipopolysaccharide-induced depression-like rats based on metabolomics study and network pharmacology. Pharm Biol. 2022 Dec;60(1):1850-1864. |
Metabolite | PE(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)); PI(16:0/20:4(5Z,8Z,11Z,14Z)); PC(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)); 2-Oxo-tricosanoic acid; Heneicosanedioic acid; Docosanedioic acid; LysoPE(0:0/20:1(11Z)); DG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)); N-cis-11,14-eicosadienoyl ethanolamine; PE(18:0/20:4(5Z,8Z,11Z,14Z)); PE(18:1(11Z)/P-16:0); PA(O-18:0/15:0); PS(20:4(8Z,11Z,14Z,17Z)/18:0); DG(20:0/20:4(5Z,8Z,11Z,14Z)/0:0); PI(16:0/22:4(10Z,13Z,16Z,19Z)); 17,20-Dimethyl prostaglandin F1a; Spiramycin II; (+)-7-epi-Syringaresinol 4'-glucoside; 15-Hexadecanolide; S-Methoprene; Ethyl palmitoleate; PS(14:1(9Z)/22:1(13Z)); PE(18:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)); (3S,6E,10E)-1,6,10,14-Phytatetraen-3-ol; Persenone B; PGP(a-13:0/i-20:0); 9S,10R-Epoxy-6Z-octadecene; MG(0:0/22:1(13Z)/0:0); Tricosanedioic acid; 3Z,6Z-Heneicosadiene; Ethyl oleate; PA(18:0/22:4(7Z,10Z,13Z,16Z)); PE(18:1(9Z)/0:0); PIM1(16:0/18:1(9Z)); (3alpha,5alpha,22R,23R)-Cholestane-3,22,23-triol; (3b,16a,21b,22a)-12-Oleanene-3,16,21,23,28-pentol-22-angeloyloxy-23-al; PGP(16:0/22:4(7,10Z,13Z,16Z)); PS(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)); Cer(d18:1/18:1(9Z)); N-(9Z-octadecenoyl)-1-beta-glucosyl-4E,6E-tetradecasphingadienine; Porson; Luteolin 4'-methyl ether 7,3'-disulfate; 1,2-(13-Methyl-tetradecanyl)-sn-glycerol; 2-(6-Carboxy-3,4,5-trihydroxyoxan-2-yl)oxy-3-hydroxybutanedioic acid; |
